- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03242993
[18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging
Biodistribution, Tumor Detection, and Radiation Dosimentry of [18F]-AZAFOL as POSITRON EMISSION TOMOGRAPHY (PET) Tracer in Folate Receptor Positive Cancer Imaging
This is a clinical trial category C as this is a first in man trial with an unapproved investigational product. Nevertheless the risk is considered low due to the low dose ≤ 10μg. No toxicity effects were observed preclinically at a dose >1000 -fold the intended dose. Open-labeled, non-blinded, non-placebo controlled, multicenter study.
Primary objective:
Assessment of biodistribution and FR-specific tumor detection of [18F]- AzaFol as a PET imaging agent in patients with FR-positive and FR-negative metastatic cancer of the ovaries or lungs.
Secondary objective:
Calculation of the effective dose to the patient according to the tissue distribution data of [18F]-AzaFol (Dosimetry)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Human research study using a radiopharmaceutical product to reveal folate receptor (FR) expression in tumors in patients.
It is known that the FR is overexpressed on a variety of tumor types. FR-positive tumors can be treated with investigational drugs specifically targeting the FR.
Although the FR-expression status may be determined by immunohistochemical staining of tumor biopsies there is a need for a non-invasive method to determine the presence of the FR on primary tumors and metastases in humans. For this purpose a radiopharmaceutical product will be used as a radiotracer. Positron Emission Tomography (PET) is an imaging method which allows assessing the distribution of radiotracers (called PET tracer). With this imaging method it is possible to obtain (semi)quantitative measures of FR-expression on tumors of at least 4-10 mm diameter in patients.
Such a folate-based radiotracer would be a very helpful tool to non-invasively discriminate FR-positive (often found in ovarian and NSC-lung cancer) from FR-negative tumors in patients with cancer disease as this would allow selecting FR-positive patients amenable to FR-targeted therapies, e.g. folate-targeted antimitotic substances such as EC145 VintafolideTM (Endocyte Inc.) or anti-FR-antibodies such as FarletuzumabTM (Morphotek Inc).
Moreover, [18F]-AzaFol PET could be used for tumor staging and monitoring therapy as well as for follow-up investigations of patients with FR-positive tumors.
Currently there is a radiopharmaceutical product for research purposes available (99mTc-EC20, EtarfolatideTM, Endocyte Inc.) which can be used for Single Photon Emission Computed Tomography (SPECT) imaging. SPECT, however, has multiple limitations compared to PET, such as inferior spatial resolution, soft tissue attenuation, lack of dynamic acquisition etc. Therefore, a PET-compound for FR imaging has been shown to image FR-positive tumors in experimental animals .
Calculations regarding the incidence and mortality of six frequent cancer types in Switzerland indicate that in over 53% of the new cases the FR is expressed (OncoSuisse, Cancer Statistics 2012).
Investigators demonstrate impressively why FR-targeting emerged as an attractive strategy for tumor diagnosis and for the development of new targeted therapy strategies .
The vitamin folic acid (pteroylglutamic acid) emerged as an almost ideal FR-targeting agent because of the high affine binding to the FR (KD < 1 nM).
Due to the small size and vitamin character of folic acid, it is non-immunogenic and non-toxic.
In spite of a large number of folate-based nuclear imaging agents which have been developed in the last two decades only one SPECT radiotracer (99mTc-EC20, EtarfolatideTM) is currently being used in clinical trials in the U.S. for SPECT imaging. For over a decade investigators have been focusing research activities on the development of a 18F-based folate radiotracer for PET imaging (13-16). Recently, a novel folate radiotracer has been developed, 3'-aza-3-[18F]fluorofolic acid (herein referred to as [18F]-AzaFol), for PET imaging purposes.
Compared to SPECT, PET is the more sensitive nuclear imaging method which provides images of an improved resolution and the possibility for accurate quantification of accumulated radioactivity in tumor lesions.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Vaud
-
Lausanne, Vaud, Switzerland, 1011
- Lausanne University Hospitals
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with cancer of the ovaries (adenocarcinoma) or non-small cell lung cancer (adenocarcinoma, squameous cell cancer or other histology) having active tumor with an indication for a systemic treatment in first or further line.
- Last systemic treatment should not applied within 3 weeks before performing study exam
- Male and female patients 18 years and older,
- Voluntarily signed Informed Consent after being informed
Inclusion criteria for [18F]-AzaFol PET (enrollment into study):
- FR-positive histology in routinely acquired biopsy samples (30 Patients)
- FR-negative histology in routinely acquired biopsy samples (6 Patients)
Exclusion Criteria:
- contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product,
- women who are pregnant or breast feeding,
- women with the intention to become pregnant during the course of the study,
- other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease),
- Renal clearance < 60 mL/min; liver transaminases ≥ 3-fold increased; bilirubin > 1.5-fold increased; Hb < 8 g/dl; Tc < 100'000, ANC < 1'500/ul
- ECOG 3-4
- known or suspected non-compliance, drug or alcohol abuse,
- inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the subject,
- Participation in another study with an investigational drug during the present study and 7 days thereafter.
- Enrolment of the investigator, his family members, employees and other dependent persons
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: treatment group
all patients successfully enrolled will be assigned to the treatment group: 1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to [18F]-AzaFol |
[18F]-AzaFol is a radiotracer produced at ETH Hönggerberg in a radiopharmaceutical GMP facility.
The drug product is provided as sterile solution for intravenous injection in a glass vial containing 6 mL of formulated product, the maximal applicable dose being 600 MBq.
For the purpose of this study only 1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to [18F]-AzaFol. Due to this low dose of a single injection of folic acid it is unlikely that adverse events would occur. Folarell® is a folic acid preparation for intravenous or intramuscular injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SUV values and volume of tracer uptake of all suspected positive lesions
Time Frame: day 0
|
SUVmax g/ml SUVmean42% g/ml lesion seen on SOC : mm |
day 0
|
Potential change of overall staging
Time Frame: day 0
|
TNM staging
|
day 0
|
Lesion detection rate in comparison to SOC (CT and/or MR and/or FDG performed within 4 weeks of PET imaging).
Time Frame: day 0
|
% (percentage)
|
day 0
|
Estimation of gained information using this tracer
Time Frame: day 0
|
uptake yes / no
|
day 0
|
quantitative estimations
Time Frame: day 0
|
SUV values for ROC analysis g/ml
|
day 0
|
General estimation of gained confidence in changing/adapting therapy based on this image
Time Frame: day 0
|
continuous % variable of confidence
|
day 0
|
Available biopsy results can be used as further variables to better assess the performance of [18F]-AzaFol
Time Frame: day 0
|
+ / - ( positive or negative)
|
day 0
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Calculation of the effective dose to the patient according to the tissue distribution data of [18F]-AzaFol (Dosimetry)
Time Frame: day 0
|
The secondary outcome is the calculated tissue distribution data of [18F]-AzaFol obtained in humans.
The effective dose for all organs will be calculated using the OLINDA software (version 1.0).
The data will be compared to the estimated data from our preclinical data set.
This will provide the radiation dosimetry values as well as quantitative biodistribution over all relevant organs.
|
day 0
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: John Prior, Prof, Lausanne University Hospitals
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PET - FOL - I
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Ovarian Cancer
-
Sheba Medical CenterUnknownMetastatic Ovarian CancerIsrael
-
Dana-Farber Cancer InstituteAstraZenecaTerminatedRecurrent Ovarian Carcinoma | Recurrent Cervical Carcinoma | Recurrent Endometrial Cancer | Metastatic Endometrial Cancer | Metastatic Cervical Cancer | Recurrent Vaginal Cancer | Recurrent Vulvar Cancer | Metastatic Ovarian Cancer | Recurrent Gynecological Cancer | Metastatic Vaginal Cancer | Metastatic...United States
-
Tampere University HospitalUniversity of Turku; University of Helsinki; Tampere University; Aalto UniversityRecruitingKidney Cancer | Breast Cancer | Metastatic Renal Cell Carcinoma | Ovarian Cancer | Prostate Cancer | Metastatic Breast Cancer | Metastatic Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Ovarian Cancer | Metastatic Renal Cancer | Metastatic Kidney Cancer | Metastatic Ovary CancerFinland
-
Inge Marie SvaneRecruitingPeritoneal Cancer | Metastatic Ovarian Cancer | Metastatic Fallopian Tube CancerDenmark
-
Dana-Farber Cancer InstituteNovartisTerminatedMetastatic Hormone-Receptor-Positive (HR+) Breast Cancer | HER2-Negative Breast Cancer | Metastatic Epithelial Ovarian CancerUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Colorectal Cancer | Metastatic Pancreatic Cancer | Metastatic Breast Carcinoma | Metastatic Ovarian Cancer | Metastatic Endocrine Tumors/ Neuroendocrine TumorsUnited States
-
IpsenCompletedMetastatic Renal Cell Cancer | Advanced or Metastatic Hepatocellular Cancer | Advanced or Metastatic Ovarian Cancer | Advanced or Metastatic Gastric CarcinomaBelgium, Canada, France, Spain, United Kingdom
-
AstraZenecaActive, not recruitingAdvanced Ovarian Cancer | Paclitaxel | Carboplatin | Triple Negative Metastatic Breast CancerBelgium, Netherlands, United Kingdom
-
University of Michigan Rogel Cancer CenterPfizer; Acrotech Biopharma Inc.RecruitingMetastatic Breast Cancer | Metastatic Castration-resistant Prostate Cancer | Metastatic Ovarian CarcinomaUnited States
-
NiKang Therapeutics, Inc.RecruitingSmall Cell Lung Carcinoma | Gastric Cancer | Ovarian Neoplasms | Ovarian Cancer | Solid Tumor | Endometrial Neoplasms | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Advanced Solid Tumor | Endometrial Cancer | Small-cell Lung Cancer | Platinum-resistant Ovarian Cancer | Ovarian Carcinoma | Solid... and other conditionsUnited States
Clinical Trials on [18F]-AzaFol
-
Insel Gruppe AG, University Hospital BernPaul Scherrer Institut, Center for Proton TherapyNot yet recruitingGiant Cell ArteritisSwitzerland
-
Genentech, Inc.Completed
-
Adam BrickmanNational Institute on Aging (NIA)Completed
-
Chang Gung Memorial HospitalRecruitingProgressive Supranuclear PalsyTaiwan
-
Five Eleven Pharma, Inc.CompletedParkinson DiseaseUnited States
-
Molecular NeuroImagingCompletedAlzheimer Disease | Healthy Volunteers | Progressive Supranuclear PalsyUnited States
-
Genentech, Inc.Completed
-
Washington University School of MedicineAbbVieRecruiting
-
University of PennsylvaniaTerminated
-
Sanjiv Sam GambhirCompletedGlioma | Arthritis, Rheumatoid | Central Nervous System Neoplasms | Brain CancerUnited States